Brief: Grand Pharmaceutical Group Says Phase II Clinical Research For Stc3141 Was Accepted By NMPA
20/04/2023 13:30
April 20 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE II CLINICAL RESEARCH APPLICATION FOR GLOBAL
INNOVATIVE
PRODUCT STC3141 OF GROUP IN CHINA WAS ACCEPTED BY NMPA
Source text for Eikon: ID:
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement